anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cervical cancer and HIV are intersecting epidemics that both disproportionately affect low-income women; the impact of the socioeconomic disparity and biologic synergy of these two diseases is seen dramatically in Kenya, where cervical cancer is the most common cancer killer. HIV-infected women are at increased risk for the development of cervical precancer and cancer, develop more aggressive lesions and are affected at younger ages. Although screening for and treatment of precancer has reduced the incidence of cervical cancer to close to zero in resource-rich countries, strategies are costly and not available in most resource-limited countries. Novel testing and treatment methods that can be carried out in low-resource settings are urgently needed to prevent cervical cancer in these settings, especially among HIV-infected women. Using a cross-sectional study design, the investigators tested two potentially low-cost and effective cervical cancer screening methods: visual inspection with acetic acid (VIA) and protein biomarkers expressed in the presence of cervical dysplasia, neither of which have been well-studied in HIV-infected women. Investigators also randomized a small subset of women to undergo VIA compared to Visual Inspection with Lugol's Iodine (VILI) to compare the test characteristics of these two screening exams. In addition, remarkably little is known about the potential impact of the presence, diagnosis and treatment of human papillomavirus-related dysplasia on HIV genital shedding, a major risk factor for HIV transmission. To explore the impact of the presence, diagnosis and treatment of human papillomavirus-related cervical dysplasia on HIV-1 in genital secretions, investigators compared the levels of HIV-1 RNA found in the cervicovaginal secretions of women with no evidence of cervical dysplasia to levels in women with high-grade cervical dysplasia. They also compared the levels of HIV-1 RNA prior to and after cervical biopsy as well as up to 14 weeks after standard treatment for cervical dysplasia using loop electrosurgical excision procedure (LEEP). Results from this study will inform the prioritization and design of safe, effective and low-cost cervical cancer screening and prevention programs for HIV-infected
Adult orbital xanthogranulomatous disease (AOXGD) is a spectrum of histiocytoses with four subtypes. Mitogen-activated protein kinase (MAPK) pathway mutations have been detected in various histiocytic neoplasms, little is known about this in AOXGD. Targeted regions of cancer- and histiocytosis-related genes were analyzed and immunohistochemical staining of phosphorylated ERK (pERK), cyclin D1 and PU.1 was performed in 28 AOXGD and 10 control xanthelasma biopsies to assess MAPK pathway activation. Mutations were detected in 7/28 (25%) patients. Positive staining for pERK and/or cyclin D1 was found across all subtypes in 17/27 (63%) patients of whom 12/17 (71%) did not harbour a mutation. Xanthelasma tissue stained negative for pERK and cyclin D1. Relapse occurred in 5/7 (71%) patients with a MAPK pathway mutation compared to 8/21 (38%) patients in whom no mutation could be detected. Molecular analysis and evaluation for systemic disease is warranted to identify patients at risk of recurrent xanthomatous disease.
A novel rhesus macaque rhadinovirus, herein designated RRV, is disclosed. The genomic, cDNA and proteins sequences are provided. RRV has some similarity to human Kaposi's sarcoma-associated herpesvirus and causes Kaposi's sarcoma-like symptoms in immuno-compromised non-human primates. RRV possesses genes for both Interleukin-6 and macrophage inflammatory protein 1. The genome of RRV is useful for research, clinical and diagnostic applications aimed towards the rhadinoviruses and herpesviruses in general and KSHV in particular. In addition, methods for using RRV to produce a non-human primate model for the testing of Kaposi's sarcoma-associated herpesvirus therapeutics and vaccines are presented.
Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) (n=30) .
The carcinogenic potential of valrubicin has not been evaluated.

In vitro, valrubicin was mutagenic in the bacterial reverse mutation (Ames) assay and clastogenic in the chromosomal aberration assay in Chinese Hamster Ovary (CHO) cells.

Studies in animals evaluating the effects of valrubicin on male or female fertility have not been conducted. Based on effects on male reproductive organs in general toxicology studies in dogs with intravesical instillation, valrubicin may impair fertility in male patients. When instilled into the bladder of male dogs weekly for 6 weeks, valrubicin caused mild to moderate atrophy of the prostate with inflammation, diffuse decrease in acinar size, epithelial changes. It also caused testicular degeneration, marked germ cell depletion, spermatid giant cells and karyomegaly.
According to the present invention, there is provided a delivery vehicle including sickle red blood cells carrying a moiety. The moiety can be any type of diagnostic or therapeutic agent. The present invention further provides for a method of diagnosing systemic hypoxia, acidosis, or hypertonicity by administering sickle red blood cells to a patient and detecting the location of the sickle red blood cells. Additionally, the present invention provides for a method of therapeutic treatment of systemic hypoxia, acidosis, or hypertonicity by administering sickle red blood cells to a patient. Further, the present invention provides for a delivery vehicle that specifically localizes or concentrates at systemic hypoxia, acidosis, or hypertonicity areas. The delivery vehicle is used in diagnosing and therapeutically treating these areas of hypoxia, acidosis, or hypertonicity also. The present invention further provides for a method of making the delivery vehicle described herein.
BACKGROUND: Myxedema coma is a rare, but life-threatening endocrinological emergency. Myxedema is characterized by altered mental status, and is accompanied by hypotension, bradycardia, hypothermia, bradypnea, hyporeflexia, hyponatremia, and hypoglycemia, all stemming from reduced metabolism due to severe hypothyroidism. Additionally, patients may exhibit signs of low cardiac output, edema in the extremities, peripheral circulatory disturbances, shock, and the development of pericardial and pleural effusions, ultimately leading to confusion and coma. We present a successfully treated case of severe myxedema coma with recurrent pericardial effusion and hypotensive shock. This case is characterized by an unusual clinical presentation and required a distinct treatment strategy highlighting its exceptional rarity.
CASE: A 2-year-old boy with Down syndrome presented with recurrent pericardial effusion attributed to medication non-adherence. The critically-ill patient, experiencing a severe cardiogenic shock required mechanical ventilation and inotropic infusions in the pediatric intensive care unit. Elevated thyroid stimulating hormone (TSH), and low free T4 (fT4) and free T3 (fT3) levels prompted consideration of myxedema coma. Upon reviewing the patient's medical history, it was ascertained that he had an ongoing diagnosis of primary hypothyroidism, and exhibited non-adherence to the prescribed treatment regimen and failed to attend scheduled outpatient clinic appointments for follow-up assessments. The treatment plan, devised by the pediatric endocrinology team, included the peroral administration of L-thyroxine (L-T4) at a dose of 50 micrograms per day. After beginning regular oral L-T4 treatment, a gradual improvement in the patient's condition was observed. Notably, by the 15th day of oral therapy, the patient had made a full recovery. Contrary to the recommended intravenous treatment for myxedema coma, this patient was successfully treated with oral levothyroxine, due to the unavailability of the parenteral form in Türkiye.
CONCLUSIONS: This case report presents an instance of non-adherence to L-T4 therapy, which subsequently progressed to severe myxedema coma. Changes in neurologic status and hemodynamic instability in a patient with a history of hypothyroidism should raise the concern of nonadherence and, though rare, myxedema coma should be in the differential diagnosis.
Background: In Chronic Kidney Disease patients, it is crucial to begin treatment as soon as possible in order to minimize the complication-related risks. Encouraging patients to adhere to their treatment plans is a great challenge for health care professionals. Objectives: The aim of this study is to evaluate the impact of a nutrition educational programme on the hyperphosphatemia using the transtheoretical model of eating behavior. Subjects and Methods: A prospective Interventional study is being conducted in a dialysis centre with 180 stage 5D Chronic Kidney Disease patients who exhibit phosphate serum levels \> 5.5 mg/dL. The educational intervention consists of lectures and group dynamics sessions performed during dialysis sessions. Anthropometric (weight, height, body mass index), clinical, demographic (sex, age, time on dialysis programme, literacy/schooling) and laboratory parameters (phosphate serum levels) will be evaluated and the transtheoretical model of eating behavior (TMFB) will be applied pre- and post-intervention. Reduction of phosphate serum levels and positive/negative behavioral changes will be the evaluated outcomes. Statistical Analyses will be carried out in order to compare the effect of educational programme on phosphate serum levels and on the behaviour changes.
In sub-Saharan Africa, HIV is predominantly transmitted via discordant sexual relationships. With the availability of antiretroviral (ARV) medications, individuals infected with HIV can live relatively normal productive lives. Societal and cultural expectations as well as personal reproductive intentions drive HIV positive women in discordant relationships to conceive. Approximately 50% of HIV infected couples desire children. However, a safe and effective method of conception that minimizes the risk of sexual HIV transmission in HIV discordant couples with a positive woman and negative man has yet to be examined. To date, published studies have evaluated assisted reproductive methods in HIV discordant couples with a positive man to decrease the risk of HIV transmission. The investigators intend to evaluate the acceptability, feasibility and efficacy of vaginal insemination with semen for conception in HIV discordant (female positive, male negative) relationships in Kenya. In this pilot study, HIV discordant couples (female positive, male negative) desiring pregnancy will receive targeted reproductive counseling through the Safer and Healthy Conception Program for 6 months. This program will emphasize the consistent use of male condoms and teach couples assisted vaginal insemination for conception to minimize the risk of sexual HIV transmission.The investigators will compare the frequency of male condom use before and after intervention with an audio computer-assisted self-interview validated by random measurement of prostate specific antigen of vaginal secretions. The incidence of pregnancy following vaginal insemination will also be measured. The investigators hypothesize that our findings will provide evidence to support the routine use of vaginal insemination as a safe method of conception in HIV discordant couples (female positive, male negative). This pilot study is of significant public health importance because the use of vaginal insemination for conception in HIV discordant couples (female positive, male negative) is expected to reduce the likelihood of riskier sexual practices for childbearing and decrease the incidence of HIV in Sub-Saharan Africa.
FIELD: veterinary science. SUBSTANCE: invention relates to production of medicinal agents used in treatment of cattle, horses and pigs with putrid and spore sicknesses of hoofs, necrobacteriosis, pododermatitis and infected wounds. Preparation shows broad spectrum of virucidal and bactericidal effect with respect to gram-negative, gram-positive microorganisms including spore forms and mycoplasmas. Preparation is able to penetrate into bacterial cells and viruses and provides formation of moisture-aero-penetrable bactericidal film based on adhesive properties of the preparation promoting to active regeneration of damaged cells. Bactericidal preparation shows the enhanced curative effectiveness and stability in storage. Preparation has no odor. The curative effectiveness of preparation is estimated to be 98%. EFFECT: enhanced and valuable properties of preparation. 2 ex
An analysis module is provided in the invention. The analysis module is connected with a database containing several data. The analysis module comprises an analysis unit and a database managing system. The analysis unit is developed by a development software to combine HHT algorithm and an automatic data-loading program. The database managing system is integrated in the analysis unit and connected with the database. The data are transferred to the analysis unit by the database managing system, and the analysis unit is used to load the data by the automatic data-loading program and analyzes the data.
In the intervention group, "Ketamine Hydrochloride 50Mg/1mL" was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds). Patient assessment was performed before and two minutes after ketamine injection, and then every 5 minutes after the reduction of the fracture, by an anesthetist blind to the type of intervention.
Various immunologically active proteins of Borrelia burgdorferi have been prepared in micro-organisms by genetic engineering techniques. To this end, the specific DNA sequences were selected from a B. burgdorferi gene bank, using suitable search methods, or represented directly by DNA amplification with selected hydridation samples and placed under the control of inducible promoters such as the lac promoter. By describing efficient purification processes for the anti-gene expressed, the proteins could be made available in a suitable fashion. These proteins can be used to produce specific and sensitive diagnostic test kits. Selective combination of the immunologically active proteins makes accurate diagnosis possible. In addition, monoclonal antibodies are produced which can be used as reagents for the detection of the exciter directly from test samples or after cultivation. The DNA sequences specific to Borrelia burgdorferi can be used for the direct detection of the offender in patient samples (e.g. by PCR reaction).
1. A polyol beta-interferon conjugate having a polyol moiety covalently bound to Cys<17> of human beta-interferon. 2. The polyol beta-interferon conjugate according to claim 1, wherein said polyol moiety is a polyalkylene glycol moiety. 3.The polyol beta -interferon conjugate according to claim 2, wherein said polyalkylene glycol moiety is a polyethylene glycol (PEG) moiety. 4. The polyol beta-interferon conjugate according to any of claims 1-3, wherein the polyol beta-interferon conjugate has the same or higher beta-interferon activity as native human beta-interferon. 5. A process for producing the polyol beta-interferon conjugate according to claim 1, comprising the steps of: reacting beta-interferon with a thiol-reactive polyol agent to site specifically and covalently attach a polyol moiety to Cys<17> of human beta-interferon to produce a polyol beta-interferon conjugate; and recovering the produced polyol beta-interferon conjugate. 6. The process according to claim 5, wherein the thiol-reactive polyol agent is a thiol-reactive PEGylating agent. 7. The process according to either claim 5 or claim 6, wherein the thiol-reactive polyol agent is mono-methoxylated. 8. The process according to either claim 5 or claim 6, wherein the thiol-reactive polyol agent is bifunctional. 9. The process according to either claim 5 or claim 6, wherein the thiol-reactive polyol agent is a polyol derivative having a functional group selected from the group consisting of orthopyridyl disulfide, vinyl sulfone, maleimide and iodoacetamide. 10. The process according to either claim 5 or claim 6, wherein the thiol-reactive polyol agent is an orthopyridyl disulfide derivative of a mono-methoxylated polyol. 11. The process according to claim 5, wherein the reacting step is carried out at an acidic pH wherein beta-interferon is stable. 12. A pharmaceutical composition, comprising a polyol beta-interferon conjugate according to any one of claims1- 3, as an active ingredient and a pharmaceutically acceptable carrier, excipient or auxiliary agent. 13. A method for treating infections, tumors and autoimmune and inflammatory diseases comprising administering an effective amount of the pharmaceutical composition according to claim 12 to a subject in need thereof.
INTRODUCTION: The use of autologous blood transfusions in oncologic surgeries is somewhat controversial due to the potential risk of disease dissemination through the salvage process. On the other hand, autologous blood transfusion can prevent the potential negative effects of allogenic blood transfusions and reduce use of valuable resources.
METHODS: This study included 106 adult patients who underwent oncologic liver surgery at our institution between December 2015 and June 2019. The patients were divided into two groups: the Cell Saver group (operated between January 2018 and June 2019) and the control group (operated between December 2015 and December 2017). The Cell Saver device was present in the operating room for the Cell Saver group, and blood was retransfused if a certain amount of blood loss occurred. Data analysis focused on outcomes such as blood transfusion requirements, overall survival, recurrence-free survival, hemoglobin levels, hospital stay, and complications. Patient records provided relevant information on demographics, surgery details, pathology, and outcomes for both groups.
RESULTS: Autologous blood transfusion was found to reduce the amount of blood units needed (4.0 units (control group) versus 0.4 units (Cell Saver group) P =0.029. Kaplan-Meier curves showed no difference for both overall survival 471.6 days (Cell Saver group) versus 468.3 days (control group) ( P =0.219) and 488.9 days (Cell Saver group) versus 487.2 days (control group) ( P =0.993) and disease-free survival ( P =0.553) and ( P =0.735) for primary hepatic tumors and hepatic metastasis respectively between the Cell Saver and control groups. Overall survival regardless of the type of tumor was similar to the control group (485.4 days vs. 481.9 days) ( P =0.503). Survival was significantly lower for minor hepatectomies (516.0 days vs. 517.4 days) ( P =0.050) in the Cell Saver group, major hepatectomies showed no difference in overall survival (470.2 days vs. 466.4 days) ( P =0.868). No impact on disease recurrence was found between patients who received autologous blood transfusions versus those who did not.
CONCLUSION: The use of Cell Saver should not be avoided in oncologic surgeries of the liver. Use of Cell Saver for major hepatectomies might be more beneficial as OS was significantly lower for the Cell Saver group for patients who underwent minor hepactomies. Further research is needed to explain this conflicting result. Nonetheless, the use of Cell Saver in autologous blood transfusions can reduce the use of valuable resources and the risks associated with allogenic blood transfusions.
Patients receive poziotinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
FOXO4 was previously identified as a potential biomarker and therapeutic target for postmenopausal osteoporosis (PMO) using bioinformatic analysis, but its specific function and molecular mechanism in the progression of osteoporosis was not reported. The current study was designed to investigate the biological function and underlying mechanism of FOXO4 in PMO. Our results showed that FOXO4 expression was significantly upregulated in the serum samples of PMO patients, which was also negatively correlated with the expression of osteogenesis genes (OCN and ALP). In addition, FOXO4 depletion alleviated osteoporosis by facilitating osteogenic differentiation and inhibiting adipogenic differentiation in human bone marrow mesenchymal stem cells (hBMSCs). Overexpression of FOXO4 exerted the opposite effects on the osteogenic/adipogenic differentiation in hBMSCs. Moreover, FOXO4 knockdown activated the Wnt/β-catenin signaling whereas the inhibition of Wnt/β-catenin signaling overturned the effects of FOXO4 deficiency on osteoporosis. Furthermore, FOXO4 upregulation in PMO was caused by CBP-induced acetylation. In summary, our data demonstrated that FOXO4 was a potent biomarker for PMO and mediated the balance between osteogenesis and adipogenesis in hBMSCs by regulating Wnt/β-catenin signaling.
The non-natural fiber or filament composition comprises an herbal masterbatch, a base polymer powder or a polymer, and one or more additives such as coupling agent, UV stabilizer, antioxidant, Antistatic agent, colorants, pigments, and the like. The herbal masterbatch further comprises an extract of at-least a natural or herbal product. The herbal masterbatch further provides multiple functional benefits such as anti-microbial, anti-odor, cooling effect etc. to the non-natural fiber or filament. Further, the method of preparing the natural or herbal masterbatch, comprises the steps of grinding at-least one of an herbal or natural products to produce an herbal extract having a particle size of less than or equal to 100 microns, or preferably less than 50 microns, or more preferably less than 25 microns, and mixing or blending the herbal extract with a coupling agent, a base polymer, and one or more from the additives such as Coupling agent, UV stabilizer, antioxidant, Antistatic agent, colorants, pigments, and the like, in a high speed mixer. In one embodiment, drawing a yarn or filament or fiber from the herbal masterbatch resulted into the non-natural fiber or filament. In another embodiment, the blended mix is extruded together through conventional spinning processes known in the art to form the non-natural fiber or filament having denier range between 0.3 DPF to 30 DPF exhibiting multiple functional benefits.
PURPOSE: A composition containing Perillae Semen ethanol extract is provided to suppress lung cancer cell growth and to prevent and treat lung cancer. CONSTITUTION: A composition for preventing and treating lung cancer contains Perillae Semen ethanol extract as an active ingredient, prepared by extracting at 50 Deg. C. for 24. The ethanol is 95% ethanol. The composition contains pharmaceutically acceptable carriers or diluents. [Reference numerals] (AA) Perillae Semen
Subjects in this arm will train their respiratory muscles at home. The training protocol will use progressively higher pressure threshold training valves to provide respiratory muscle strength training at a pressure threshold greater than 70% maximum inspiratory (MIP) and expiratory (MEP) pressures. The total daily training time should be 20 to 30 minutes in duration.